Eledon Pharmaceuticals, Inc. (ELDN) Market Cap
Eledon Pharmaceuticals, Inc. has a market capitalization of $239.2M.
Financials based on reported quarter end 2025-12-31
Price: $3.99
▼ -0.15 (-3.62%)
Market Cap: 239.20M
NASDAQ · time unavailable
CEO: David-Alexandre C. Gros
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2014-09-17
Website: https://eledon.com
Eledon Pharmaceuticals, Inc. (ELDN) - Company Information
Market Cap: 239.20M · Sector: Healthcare
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Analyst Sentiment
Based on 4 ratings
Analyst 1Y Forecast: $7.00
Average target (based on 2 sources)
Consensus Price Target
Low
$5
Median
$5
High
$5
Average
$5
Potential Upside: 25.3%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"ELDN reported no revenue for the period ending December 31, 2025, reflecting a pre-revenue status. The company has recorded a net loss of $10,447,000, resulting in a negative EPS of $0.14. Operationally, cash outflows are pronounced, with operating cash flow at -$14,091,000 and free cash flow mirroring this negative trend. On the balance sheet, ELDN holds total assets of $169,009,000 against liabilities of $32,230,000, indicating a strong asset base relative to liabilities, and net debt is at -$22,167,000, highlighting a cash position greater than debt obligations. Despite this, the overall company health is challenged by persistent losses. Shareholder returns are currently non-existent, as no dividends have been paid and the stock price has experienced a decline of approximately 20% over the past year. However, the stock has shown a robust performance in the year-to-date with a gain of 78.4%. Overall, the minimal revenue and ongoing losses cast a shadow over future growth potential, despite a solid balance sheet position."
Revenue Growth
The company has no revenue.
Profitability
Significant net losses with negative EPS.
Cash Flow Quality
Ongoing negative cash flow from operations.
Leverage & Balance Sheet
Strong asset position with low liabilities.
Shareholder Returns
No dividends and value decline in the past year.
Analyst Sentiment & Valuation
Uncertain future with a low valuation as indicated by price performance.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Management’s tone is strongly constructive: Q1’s message centers on Tegoprubart’s early kidney-transplant proof-of-concept (no acute rejection in first 3 Phase 1b patients; mean eGFR >70 up to week 31) plus a runway-boosting financing (up to $185M gross with $35M upfront). However, the Q&A reveals specific clinical execution hurdles that could affect enrollment/consistency of outcomes. BK viremia—present in ~10–20% of transplant contexts—already forced a discontinuation in Phase 1b, and BESTOW mitigation relies on PI discretion to wean other immunosuppressants and possibly delay Tegoprubart dosing (with anti-drug antibody risk if pauses are too long). On efficacy measurement, the BAR is high: BESTOW must show statistically superior 12-month eGFR versus tacrolimus, and steroid-taper benefits will not be captured via dedicated exploratory endpoints (instead via overall safety/side-effect comparisons). Analyst questions focused on partner rationale and operational contingencies; management answered, but concrete control over these risks appears partially investigator-dependent.
Growth Catalysts
- Phase 1b kidney transplantation open-label update: no acute rejection observed in first 3 participants at 56, 167, and 232 days
- Phase 1b kidney transplant graft function: reported eGFRs 54, 85, and 77 at latest time points (49, 154, and 217 days), with mean eGFR > 70 as far out as week 31
- Updated/ongoing execution: enrolled 6 Phase 1b participants total; continued enrollment with expected BESTOW initiation midyear
Business Development
- Private placement financing led by BVF Partners and Armistice Capital
- Sanofi participated in financing (no special rights described vs other investors)
- Collaboration with CareDx used for biomarker/algorithm work in BESTOW, including iBox scoring as an exploratory endpoint
Financial Highlights
- Net loss: $10.8M ($0.75/share) vs $9.9M ($0.69/share) in Q1 2022
- R&D expenses: $8.1M vs $6.6M (+$1.5M), driven by higher clinical development costs (external CROs +$2.1M) and increased headcount; partially offset by decreases in stock-based comp, manufacturing, and consulting
- G&A expenses: $3.0M vs $3.2M (−$0.2M) primarily from lower stock-based compensation
- Balance sheet cash at Q1 end: ~$46.5M
- Capital raised: private placement up to $185M gross; $35M upfront; up to $105M contingent on milestones/weighted share price/trading volume; plus up to $45M upon full warrant exercise
Capital Funding
- Private placement: up to $185M gross proceeds
- Upfront cash received: $35M
- Potential additional funds: up to $105M upon achievement of specified clinical development milestones and market/trading conditions; plus up to $45M from full warrant exercise
- Ending cash: ~$46.5M as of March 31, 2023
Strategy & Ops
- Resource shift/deprioritization: IgAN program de-prioritized; winding down vast majority of IgAN activity and spend in Q2 2023
- BESTOW trial design: 120 participants, randomized 1:1, Tegoprubart q21 days vs oral tacrolimus BID; primary endpoint mean eGFR at 12 months
Market Outlook
- Phase 2 BESTOW initiation: expected midyear 2023
- Phase 1b updated data venue timing: medical meeting towards end of 2023 (e.g., Kidney Week considered); expectation that all patients will likely have >90 days on drug by then (with follow-up out to ~1 year)
Risks & Headwinds
- BK viremia risk in transplant: reported as occurring in ~10% to 20% of studies (site/country/regimen dependent); occurred in 1 patient during Phase 1b
- Operational mitigation for BK viremia: standard practice is PI discretion to wean off immunosuppressants used to prevent rejection based on viral load; balance between controlling viral load and preventing rejection
- Potential Tegoprubart management under viral rise: as biologics are dosed every 3 weeks, investigators may delay next infusion and adjust concomitant immunosuppressants; risk of anti-drug antibody responses if infusions paused too long
- Steroid tapering endpoint capture limitation: no steroid-taper-specific exploratory endpoints in BESTOW; steroid benefit to be reflected within comparative safety profile and side-effect differences (standard-of-care vs Tegoprubart arms removing steroids by ~6 months)
- Clinical efficacy risk remains: BESTOW is designed as a superiority study on 12-month eGFR, requiring statistically superior delta vs tacrolimus; management emphasized need for meaningful eGFR delta
Sentiment: MIXED
Note: This summary was synthesized by AI from the ELDN Q1 2023 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.